18 July 2023— As Johnson & Johnson’s (J&J) 20-year primary patent on the critical, lifesaving drug-resistant tuberculosis (DR-TB) drug bedaquiline expires in the majority of countries, including India, Doctors Without…
18 July 2023— As Johnson & Johnson’s (J&J) 20-year primary patent on the critical, lifesaving drug-resistant tuberculosis (DR-TB) drug bedaquiline expires in the majority of countries, including India, Doctors Without…